Assessment of Tachykinin Receptor 3′ Gene Polymorphism rs3733631 in Rosacea
Table 2
Distribution of genotypes among patients with rosacea and healthy controls.
Controls
Patients
OR†
95% CI
value
Total
Genotype
C/C
106 (87.7)
108 (84.4)
Ref.
C/G
14 (11.6)
17 (13.3)
1.21
0.57–2.58
0.621
G/G
1 (0.8)
3 (2.3)
3.16
0.32–31.07
0.325
Recessive model
C/C
106 (87.7)
108 (84.4)
Ref.
C/G or G/G
15 (12.4)
20 (15.6)
1.34
0.65–2.76
0.433
Allele contrast
C
226 (93.4)
233 (91.0)
Ref.
G
16 (6.6)
23 (9.0)
1.43
0.73–2.78
0.295
Males
Genotype
C/C
47 (87.0)
41 (77.3)
Ref.
C/G
7 (13.0)
9 (17.0)
1.48
0.50–4.34
0.478
G/G
0 (0.0)
3 (5.7)
—
—
—
Recessive model
C/C
47 (87.0)
41 (77.3)
Ref.
C/G or G/G
7 (13.0)
12 (22.7)
1.97
0.71–1.02
0.193
Allele contrast
C
101 (93.5)
91 (85.8)
Ref.
G
7 (6.5)
15 (14.2)
2.38
0.93–6.11
0.071
Females
Genotype
C/C
59 (88.1)
67 (89.3)
Ref.
C/G
7 (10.4)
8 (10.7)
1.02
0.35–2.99
0.973
G/G
1 (1.5)
0 (0.0)
—
—
—
Recessive model
C/C
59 (88.1)
67 (89.3)
Ref.
C/G or G/G
8 (11.9)
8 (10.7)
0.9
0.32–2.54
0.835
Allele contrast
C
125 (93.3)
142 (94.7)
Ref.
G
9 (6.7)
8 (5.3)
0.8
0.30–2.13
0.65
Note: statistical significance for differences in genotype, G-containing genotype, and allelic frequencies between patients with rosacea and healthy controls: (i) = 1.113, df = 2, and = 0.573; = 0.537, df = 1, and = 0.464; = 0.970, df = 1, and = 0.325 among the entire cohort; (ii) = 3.650, df = 1, and = 0.161; = 1.716, df = 1, and = 0.190; = 3.412, df = 1, and = 0.065 among males; (iii) = 1.127, df = 1, and = 0.569; = 0.057, df = 1, and = 0.811; = 0.241, df = 1, and = 0.624 among females. Data are number of subjects and percentage (%); †adjusted for age and gender.
